Glucosa Fresenius Kabi

Glucosa Fresenius Kabi is a sterile injectable solution containing glucose monohydrate as the active ingredient. It is supplied in a solution for injection format, with the specific concentration not disclosed in the public data. The product is marketed in the European Union and is classified as an excipient/solvent used in parenteral nutrition. It is available by prescription only and administered intravenously. It supplies rapid glucose for clinical use.

Glucosa Fresenius Kabi is used in clinical settings where rapid intravenous glucose delivery is required.

- Parenteral nutrition to meet carbohydrate and caloric energy needs in patients who cannot consume food orally or enterally. - Treatment of acute hypoglycemia in emergency or perioperative settings when oral glucose administration is impractical or contraindicated. - Support during surgical procedures to maintain stable blood glucose concentrations and prevent intra‑operative metabolic disturbances. - Management of metabolic disorders such as glycogen storage disease or insulinoma that require controlled intravenous glucose infusion. - Dilution medium for compatible intravenous medications, providing an energy source while preserving drug stability.

Glucosa Fresenius Kabi, as an intravenous glucose solution, may be associated with certain adverse reactions that vary in frequency and severity.

Common: - Local irritation or pain at the injection site. - Transient hyperglycemia leading to elevated blood glucose measurements. - Mild electrolyte shifts, particularly potassium changes. - Nausea or vomiting when administered rapidly. - Mild headache or dizziness during infusion. - Temporary increase in serum triglycerides.

Serious: - Severe hyperglycemia with risk of osmotic diuresis and dehydration. - Hypersensitivity reactions including rash, urticaria, or anaphylaxis. - Fluid overload, especially in patients with cardiac or renal impairment. - Metabolic acidosis in the context of massive glucose infusion. - Hyperosmolar state leading to neurological symptoms in extreme cases.

When using Glucosa Fresenius Kabi, clinicians should observe specific precautions to minimize risks and ensure safe administration.

- Verify patient’s blood glucose level before infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with impaired renal or cardiac function to prevent fluid overload. - Use aseptic technique and inspect the solution for particulate matter or discoloration prior to administration. - Monitor electrolytes, especially potassium and phosphate, during and after infusion. - Consider compatibility with other intravenous drugs; avoid mixing with solutions that may precipitate. - Document infusion parameters and patient response in the medical record. - Educate patients and caregivers about signs of hyperglycemia and allergic reactions.

Glucosa Fresenius Kabi may interact with certain medications or clinical conditions; awareness of these interactions helps optimize therapy.

Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring, which can precipitate severe hypoglycemia. - Mixing with calcium‑containing solutions that may cause precipitation of calcium gluconate. - Concurrent use of hyperosmolar agents that could exacerbate fluid overload.

Use with caution: - Concurrent diuretics that may alter electrolyte balance; monitor potassium and phosphate levels. - Patients receiving total parenteral nutrition; adjust overall carbohydrate load to prevent excess caloric intake. - Use in patients with renal or cardiac insufficiency; titrate infusion rate and monitor fluid status closely.